Deerfield leads oncology startup Dracen Pharma’s $40M series A

money
Dracen Pharma has an exclusive agreement with Johns Hopkins and the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences to license the immuno-metabolism tech and develop drug candidates. (pasja1000)

Deerfield Management will put up $36 million of Dracen Pharma’s $40 million series A round. The funds will propel the startup’s cancer programs into clinical trials.

The Baltimore-based company came to life in 2017 and is working on cancer treatments based on research from Barbara Slusher and Jonathan Powell, M.D., at the Johns Hopkins University. The company signed an exclusive agreement with JHU and the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences to license the technology and develop drug candidates.

The Baltimore Business Journal reported in January that the startup was on the hunt for office and lab space and hopes to have programs in clinical development by 2019. Slusher and Powell will serve as close advisers to the company, which was looking to hire a core team of 12 staffers, CEO Tom Estok told the BBJ.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Big Pharma trio drive cancer metabolism upstart to $18M Series A round

Dracen is working on drugs targeting immuno-metabolism, an approach that combines immuno-oncology and cancer metabolism. It is developing a platform of glutamine antagonists that simultaneously trigger a patient’s immune response to fight cancer and disrupt the energy sources on which tumors rely to stay alive. The company is developing its candidates for use as monotherapies, as well as in combination with other meds, including checkpoint inhibitors. The tech may also have applications in autoimmune and inflammatory diseases.

Although it seems like everyone and their mother has been diving into immuno-oncology, merging it with cancer metabolism is relatively new.

“We believe immuno-metabolism is the next big area for immuno-oncology therapeutics, as it has the potential to generate broad-spectrum immune stimulation either alone or in combination with checkpoint inhibitors,” said Kyn Therapeutics CEO Mark Manfred in December, when his company emerged from stealth.

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.